We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > STEGLATRO

News List

Merck's Steglatro shows limited promise with heart failure hospitalization data fiercepharma
September 01, 2020
Late to the party against its SGLT2 diabetes rivals, Merck & Co.'s Steglatro has also tracked way behind in the class' growing presence in heart failure.
MSD/Pfizer's diabetes drug Steglatro hits goal in CV outcomes trial pharmatimes
June 22, 2020
MSD and Pfizer have unveiled data from the Phase III VERTIS CV cardiovascular (CV) outcomes trial which add further evidence on the safety of their diabetes drug Steglatro (ertugliflozin).
Merck and Pfizer’s SGLT2 inhibitor STEGLATRO meets primary endpoint in VERTIS CV trial pharmaceutical-business-review
June 18, 2020
Merck, known as MSD outside the United States and Canada, and Pfizer Inc., announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated STEGLATRO (ertugliflozin) ...